Remdesivir and standard care vs placebo or usual care
Adverse events: all grades · hospitalised individuals with COVID‐19 (moderate to severe disease)
Remdesivir and standard care showed no clear difference in adverse events (any grade) at up to day 28 compared with standard care (plus/minus placebo) (low certainty).
1 finding from 1 review
- RR 1.04 [0.92, 1.18]4 studies · 2498 participantsLow